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We	  need	  much	  more	  baseline	  whole	  
genome	  sequencing	  in	  large	  pedigrees	  





Penetrance	  and	  Expressivity	  
•  We	  do	  not	  really	  know	  the	  penetrance	  or	  
expressivity	  of	  	  preBy	  much	  ALL	  muta@ons	  in	  
humans,	  as	  we	  have	  not	  systema@cally	  
sequenced	  or	  karyotyped	  any	  gene@c	  altera@on	  
in	  MILLIONS	  of	  well-­‐phenotyped	  people.	  
•  Do	  single	  muta@ons	  drive	  outcome	  
predominately,	  or	  are	  the	  results	  modified	  
substan@ally	  by	  other	  muta@ons	  and/or	  
environment?	  	  Is	  there	  really	  such	  a	  thing	  as	  
gene@c	  determinism	  for	  MANY	  muta@ons?	  


Long-­‐range	  Plans:	  ~750	  DNA	  samples	  from	  many	  
pedigrees	  with	  455	  of	  these	  genotyped	  thus	  far	  on	  
Illumina	  610K/2.5M	  arrays	  and	  15	  with	  high-­‐depth	  
exome,	  and	  8	  with	  CG	  whole	  genomes.	  	  
A	  new	  syndrome	  and	  its	  gene@c	  basis.	  
prominence	  of	  eyes,	  down-­‐sloping	  palpebral	  fissures,	  thickened	  
eyelids,	  large	  ears,	  beaking	  of	  nose,	  flared	  nares,	  hypoplas@c	  nasal	  
alae,	  short	  columella,	  protruding	  upper	  lip,	  micro-­‐retrognathia	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This	  is	  the	  family	  in	  Utah	  in	  December	  2009.	  
I	  met	  the	  en@re	  family	  on	  March	  29,	  2010	  
Photo	  of	  mother	  
with	  son	  in	  late	  1970’s	  
First	  boy.	  Called	  “a	  liBle	  old	  man”	  by	  
the	  family.	  Died	  around	  ~1	  year	  of	  
age,	  from	  cardiac	  arrhythmias.	  
This	  is	  the	  first	  boy	  in	  the	  late	  1970’s.	  
Uncle	  #1	   Uncle	  #2	   cousin	   Proband-­‐	  SuBer	  
These	  are	  the	  Affected	  Boys	  of	  Family	  1	  in	  2009.	  	  
Affected	  males	  had	  the	  consistent	  presenta@on	  of	  an	  aged	  appearance,	  a	  dis@nct	  
and	  recognizable	  combina@on	  of	  craniofacial	  anomalies,	  post-­‐natal	  growth	  failure,	  
hypotonia,	  global	  developmental	  delays,	  cryptorchidism,	  arrhythmia,	  and	  
eventual	  death	  from	  cardiac	  failure.	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Experimental Design for Sequencing is Critical. 
  We	  performed	  X-­‐chromosome	  exon	  capture	  
with	  Agilent,	  followed	  by	  Next	  Gen	  
Sequencing	  with	  Illumina.	  
  We	  analyzed	  the	  data	  with	  ANNOVAR	  and	  
VAAST	  (Variant	  Annota2on,	  Analysis	  and	  
Search	  Tool).	  New	  computa2onal	  tools	  for	  
iden2fying	  disease-­‐causing	  muta2ons	  by	  
individual	  genome	  sequencing.	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The	  Exon	  Capture	  and	  Coverage	  was	  
high	  depth.	  
!
Table 2. Coverage Statistics in Family 1. Based on GNUMAP 



































* On chromosome X, there are 8,222 unique RefSeq exons. Of these exons, 736 were excluded from the SureSelect X-Chromosome Capture 
Kit because they were designated as pseudoautosomal or repetitive sequences (UCSC genome browser). 
Family	  now,	  with	  five	  muta2on-­‐posi2ve	  boys	  dying	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Ancestry	  Magers!	  -­‐	  Ogden	  Syndrome	  	  
The	  muta@on	  is	  necessary,	  but	  we	  do	  not	  know	  if	  it	  is	  sufficient	  to	  cause	  this	  
phenotype	  in	  ANY	  gene@c	  background.	  It	  simply	  “contributes	  to”	  the	  phenotype.	  
The	  muta2on	  disrupts	  the	  N-­‐terminal	  
acetyla2on	  machinery	  (NatA)	  in	  
human	  cells.	  	  
Slide	  courtesy	  of	  Thomas	  Arnesen	  
 Simulated	  structure	  of	  S37P	  mutant	  	  
?	  
Big	  Ques@on:	  
Max	  Doerfel	   Yiyang	  Wu	  
	  hNaa10p-­‐S37P	  is	  func2onally	  
impaired	  in	  vivo	  using	  a	  yeast	  model.	  
	  









































































































Likely	  X-­‐linked	  or	  Autosomal	  Recessive,	  with	  X-­‐linked	  being	  supported	  by	  extreme	  X-­‐
skewing	  in	  the	  mother	  	  
New	  Syndrome	  with	  Dysmorphology,	  Mental	  	  
Retarda@on,	  “Au@sm”,	  “ADHD”	  
1.5	  years	  old	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  3.5	  years	  old 	   	   	   	  7	  years	  old 	   	  	  
3	  years	  old	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  5	  years	  old 	   	   	   	  	  	  9	  years	  old 	  	  
Workup	  Ongoing	  for	  past	  10	  years	  
•  Numerous	  gene@c	  tests	  nega@ve,	  including	  nega@ve	  for	  
Fragile	  X	  and	  many	  candidate	  genes.	  
•  No	  obvious	  pathogenic	  CNVs	  –	  microarrays	  normal.	  
•  Sequenced	  whole	  genomes	  of	  Mother,	  Father	  and	  Two	  
Boys,	  using	  Complete	  Genomics,	  obtained	  data	  in	  June	  
of	  this	  year,	  i.e.	  version	  2.0	  CG	  pipeline.	  
Jason	  O’Rawe,	  	  
analyst	  
Complete	  Genomics	  chemistry	  -­‐	  combinatorial	  











Chromosome	   Posi@on	   Reference	   Coding?	   SIFT	  Score	   Score	  <=	  0.05	   Ref/Alt	  Alleles	  
X	   47307978	   G	   YES	   0.649999976	   0	   G/T	  
X	   63444792	   C	   YES	   0	   1	   C/A	  
X	   70621541	   T	   YES	   0.009999999776	   1	   T/C	  
Variant	   Reference	   Alternate	   Classifica@on	   Gene	  1	   Transcript	  1	   Exon	  1	   HGVS	  Coding	  1	   HGVS	  Protein	  1	  
X:47307978-­‐SNV	   G	   T	   Nonsyn	  SNV	   ZNF41	   NM_007130	   5	  c.1191C>A	   p.Asp397Glu	  
X:63444792-­‐SNV	   C	   A	   Nonsyn	  SNV	   ASB12	   NM_130388	   2	  c.739G>T	   p.Gly247Cys	  
X:70621541-­‐SNV	   T	   C	   Nonsyn	  SNV	   TAF1	   NM_004606	   25	  c.4010T>C	   p.Ile1337Thr	  
RANK	   Gene	   p-­‐value	   p-­‐value-­‐ci	   Score	   Variants	  
1	   ASB12	   1.56E-­‐11	   1.55557809307134e-­‐11,0.000290464582480396	   38.63056297	   chrX:63444792;38.63;C-­‐>A;G-­‐>C;0,3	  
2	   TAF1	   1.56E-­‐11	   1.55557809307134e-­‐11,0.000290464582480396	   34.51696816	   chrX:70621541;34.52;T-­‐>C;I-­‐>T;0,3	  
3	   ZNF41	   1.56E-­‐11	   1.55557809307134e-­‐11,0.000290464582480396	   32.83011803	   chrX:47307978;32.83;G-­‐>T;D-­‐>E;0,3	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Mutations in the ZNF41 Gene Are Associated with Cognitive Deficits:
Identification of a New Candidate for X-Linked Mental Retardation
Sarah A. Shoichet,1 Kirsten Hoffmann,1 Corinna Menzel,1 Udo Trautmann,2 Bettina Moser,1
Maria Hoeltzenbein,1 Bernard Echenne,3 Michael Partington,4 Hans van Bokhoven,5
Claude Moraine,6 Jean-Pierre Fryns,7 Jamel Chelly,8 Hans-Dieter Rott,2 Hans-Hilger Ropers,1
and Vera M. Kalscheuer1
1Max-Planck-Institute for Molecular Genetics, Berlin; 2Institute of Human Genetics, University of Erlangen-Nuremberg, Erlangen-Nuremberg;
3Centre Hospitalier Universitaire de Montpellier, Hoˆpital Saint-Eloi, Montpellier, France, 4Hunter Genetics and University of Newcastle,
Waratah, Australia; 5Department of Human Genetics, University Medical Centre, Nijmegen, The Netherlands; 6Services
de Ge´ne´tique–INSERM U316, CHU Bretonneau, Tours, France; 7Center for Human Genetics, Clinical Genetics Unit, Leuven, Belgium;
and 8Institut Cochin de Ge´ne´tique Moleculaire, Centre National de la Recherche Scientifique/INSERM, CHU Cochin, Paris
Nonsyndromic X-linkedmental retardation (MRX) is defined by anX-linked inheritance pattern of low IQ, problems
with adaptive behavior, and the absence of additional specific clinical features. The 13 MRX genes identified
to date account for less than one-fifth of all MRX, suggesting that numerous gene defects cause the disorder in
other families. In a female patient with severe nonsyndromic mental retardation and a de novo balanced translocation
t(X;7)(p11.3;q11.21), we have cloned the DNA fragment that contains the X-chromosomal and the autosomal break-
point. In silico sequence analysis provided no indication of a causative role for the chromosome 7 breakpoint in
mental retardation (MR), whereas, on the X chromosome, a zinc-finger gene, ZNF41, was found to be disrupted.
Expression studies indicated that ZNF41 transcripts are absent in the patient cell line, suggesting that the mental
disorder in this patient results from loss of functional ZNF41. Moreover, screening of a panel of patients with
MRX led to the identification of two other ZNF41 mutations that were not found in healthy control individuals.
A proline-to-leucine amino acid exchange is present in affected members of one family with MRX. A second family
carries an intronic splice-site mutation that results in loss of specific ZNF41 splice variants. Wild-type ZNF41
contains a highly conserved transcriptional repressor domain that is linked to mechanisms of chromatin remodeling,
a process that is defective in various other forms of MR. Our results suggest that ZNF41 is critical for cognitive
development; further studies aim to elucidate the specific mechanisms by which ZNF41 alterations lead to MR.
Introduction
Developmental delay, also referred to as “mental retar-
dation” (MR), affects an estimated 2%–3% of the popu-
lation (Chelly and Mandel 2001). Although the etiology
of MR is complex and poorly understood, recent inves-
tigations have highlighted the importance of genetic fac-
tors in cognitive development. In particular, studies of the
X chromosome have confirmed that there are numerous
specific monogenic forms of MR. Of significant historical
importance is the recognition of fragile X syndrome
(FRAXA) and the identification of the FMR1 gene (MIM
309550). FRAXA is caused by a CGG repeat expansion
in the FMR1 5′ UTR, which is then abnormally methyl-
ated. Accounting for 2%–2.5% of the established X-
Received July 22, 2003; accepted for publication September 25, 2003;
electronically published November 18, 2003.
Address for correspondence and reprints: Dr. Vera Kalscheuer,Max-
Planck-Institute for Molecular Genetics, Ihnestrasse 73, D-14195Berlin,
Germany. E-mail: kalscheu@molgen.mpg.de
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linked forms of MR (XLMR), this syndrome is the most
common cause of XLMR known at present (for review,
see Jin and Warren [2003]). XLMR is now divided into
two subgroups: syndromic XLMR (MRXS), which in-
cludes FRAXA and other MR-associated disorders that
can be defined by a set of specific clinical features, and
MRX, which includes all X-linked forms ofMR forwhich
the only consistent clinical feature is MR. To date, 30
genes responsible for MRXS and 13 genes responsible for
MRX have been cloned (Frints et al. 2002; Hahn et al.
2002; Vervoort et al. 2002). The recent discovery that
mutations in ARX (MIM 300382)—the human homo-
logue of the Drosophila gene Aristaless—are responsible
for syndromic MRX with infantile spasms, Partington
syndrome (MIM 309510), and MRX (Bienvenu et al.
2002; Stromme et al. 2002) clearly illustrates that mu-
tations in a single disease gene may result in a relatively
broad spectrum of clinical features. This phenomenon has
been observed for an increasing number of genes impli-
cated in bothMRXS andMRX, includingMECP2 (MIM
300005) (Amir et al. 1999; Couvert et al. 2001; Yntema
et al. 2002), AGTR2 (MIM 300034) (Vervoort et al.
Am. J. Hum. Gen t. 73:1341–1354, 2003
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linked forms of MR (XLMR), this syndrome is the most
common cause of XLMR known at present (for review,
see Jin and Warren [2003]). XLMR is now divided into
two subgroups: syndromic XLMR (MRXS), which in-
cludes FRAXA and other MR-associated disorders that
can be defined by a set of specific clinical features, and
MRX, which includes all X-linked forms ofMR forwhich
the only consistent clinical feature is MR. To date, 30
genes responsible for MRXS and 13 genes responsible for
MRX have been cloned (Frints et al. 2002; Hahn et al.
2002; Vervoort et al. 2002). The recent discovery that
mutations in ARX (MIM 300382)—the human homo-
logue of the Drosophila gene Aristaless—are responsible
for syndromic MRX with infantile spasms, Partington
syndrome (MIM 309510), and MRX (Bienvenu et al.
2002; Stromme et al. 2002) clearly illustrates that mu-
tations in a single disease gene may result in a relatively
broad spectrum of clinical features. This phenomenon has
been observed for an increasing number of genes impli-
cated in bothMRXS andMRX, includingMECP2 (MIM
300005) (Amir et al. 1999; Couvert et al. 2001; Yntema











































































Sanger	  valida2on:	  	  ASB12	  and	  ZNF41	  muta2ons	  
The	  muta@on	  in	  ZNF41	  may	  NOT	  be	  necessary,	  and	  it	  is	  certainly	  
NOT	  sufficient	  to	  cause	  the	  phenotype.	  
So,	  of	  course	  we	  need	  baseline	  whole	  
genome	  sequencing	  on	  everyone	  to	  at	  
least	  understand	  the	  DNA	  gene@c	  
background	  in	  each	  pedigree	  or	  clan.	  
	  
Ancestry	  MaBers!	  
How	  do	  we	  get	  to	  “whole”	  genome	  
sequencing	  for	  everyone?	  
•  Tool	  Building	  for	  Human	  Gene@cs	  
•  Can	  we	  reliably	  detect	  a	  comprehensive,	  and	  
accurate,	  set	  of	  variants	  using	  more	  than	  one	  
pipeline,	  or	  even	  more	  than	  one	  sequencing	  
playorm?	  
•  How	  much	  data	  is	  enough,	  and	  how	  reliable	  
and	  reproducible	  are	  variant	  calls?	  
	  
Moving	  Exome	  and	  WGS	  into	  a	  Clinical	  
Sezng	  requires	  both	  Analy@c	  and	  
Clinical	  Validity	  
•  Analy@cal	  Validity:	  the	  test	  is	  accurate	  with	  
high	  sensi@vity	  and	  specificity.	  
•  Clinical	  Validity:	  Given	  an	  accurate	  test	  result,	  
what	  impact	  and/or	  outcome	  does	  this	  have	  
on	  the	  individual	  person?	  

•  ~$3000	  for	  30x	  “whole”	  genome	  as	  part	  of	  
Illumina	  Genome	  Network	  on	  a	  research	  basis	  
only,	  but	  ~$5,000	  for	  whole	  genome	  
performed	  in	  a	  CLIA	  lab	  at	  Illumina.	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systems and infrastructure to facilitate health information exchange so that 
data can be easily aggregated and studied.213 Integrating whole genome 
sequence data into health records within the learning health system model 
can provide researchers with more data to perform genome-wide analyses, 
which in turn can advance clinical care. Several Institute of Medicine (IOM) 
working groups have supported these goals, outlining the desirability of 
establishing a universal health information technology system and learning 
environment that engages health care providers and patients. The IOM 
reports recommend that such a system include both genomic and clinical 
information, increased interoperability of medical records systems, and 
reduced barriers to data sharing.214 The President’s Council of Advisors 
on Science and Technology identified the lack of sharing electronic health 
records—with patients, with a patient’s health care providers at other 
organizations, with public health agencies, and with researchers—as a barrier 
to improved health care.215
Recommendation 4.1
Funders of whole genome sequencing research, relevant clinical entities, 
and the commercial sector should facilitate explicit exchange of information 
between genomic researchers and clinicians, while maintaining robust data 
protection safeguards, so that whole genome sequence and health data can be 
shared to advance genomic medicine.
Performing all whole genome sequencing in CLIA-approved laboratories 
would remove one of the barriers to data sharing. It would help ensure that 
whole genome sequencing generates high-quality data that clinicians and 
researchers can use to draw clinically relevant conclusions. It would also 
ensure that individuals who obtain their whole genome sequence data could 
share them more confidently in patient-driven research initiatives, producing 
more meaningful data. !at said, current sequencing technologies and those 
in development are diverse and evolving, and standardization is a substantial 
challenge. Ongoing efforts, such as those by the Standardization of Clinical 
Testing working group are critical to achieving standards for ensuring the 
reliability of whole genome sequencing results, and facilitating the exchange 
and use of these data.216
Op@mizing	  Variant	  Calling	  in	  Exomes	  at	  
BGI	  in	  2011	  
•  Agilent	  v2	  44	  MB	  exome	  kit	  
•  Illumina	  Hi-­‐Seq	  for	  sequencing.	  
•  Average	  coverage	  ~100-­‐150x.	  
•  Depth	  of	  sequencing	  of	  >80%	  of	  the	  target	  
region	  with	  >20	  reads	  or	  more	  per	  base	  pair.	  
•  Comparing	  various	  pipelines	  for	  alignment	  and	  
variant-­‐calling.	  
2-­‐3	  rounds	  of	  sequencing	  at	  BGI	  to	  again	  
goal	  of	  >80%	  of	  target	  region	  at	  >20	  reads	  
per	  base	  pair	  
Exome Capture Statistics K24510-84060 K24510-92157-a K24510-84615 K24510-88962 
Target region (bp) 46,401,121  46,401,121  46,401,121  46,257,379  
Raw reads 138,779,950  161,898,170  156,985,870  104,423,704  
Raw data yield (Mb) 12,490  14,571  14,129  9,398  
Reads mapped to genome 110,160,277  135,603,094  135,087,576  83,942,646  
Reads mapped to target region 68,042,793  84,379,239  80,347,146  61,207,116  
Data mapped to target region (Mb) 5,337.69  6,647.18  6,280.01  4,614.47  
Mean depth of target region 115.03 143.25 135.34 99.76 
Coverage of target region (%) 0.9948  0.9947  0.9954  0.9828  
Average read length (bp) 89.91  89.92  89.95  89.75  
Fraction of target covered >=4X 98.17  98.38  98.47  94.25  
Fraction of target covered >=10X 95.18  95.90  95.97  87.90  
Fraction of target covered >=20X 90.12  91.62  91.75  80.70  
Fraction of target covered >=30X 84.98  87.42  87.67  74.69  
Capture specificity (%) 61.52  62.12  59.25  73.16  
Fraction of unique mapped bases on or near target 65.59  65.98  63.69  85.46  
Gender test result M M M F 
Depth	  of	  Coverage	  in	  15	  exomes	  >	  20	  






















Pipelines	  Used	  on	  Same	  Set	  of	  Seq	  Data	  by	  Different	  
Analysts,	  using	  Hg19	  Reference	  Genome	  
1)  BWA	  -­‐	  GATK	  (version	  1.5)	  with	  recommended	  parameters	  	  (GATK	  IndelRealigner,	  
base	  quality	  scores	  were	  re-­‐calibrated	  by	  GATK	  Table	  Recalibra@on	  tool.	  
Genotypes	  called	  by	  GATK	  UnifiedGenotyper.	  For	  SNVs	  and	  indels.	  
	  
2)  BWA	  -­‐	  SamTools	  version	  0.1.18	  to	  generate	  genotype	  calls	  	  -­‐-­‐	  The	  “mpileup”	  
command	  in	  SamTools	  was	  used	  for	  iden@fy	  SNVs	  and	  indels.	  
	  
3)  SOAP-­‐Align	  –	  SOAPsnp	  for	  SNVs–	  and	  BWA-­‐SOAPindel	  (adopts	  local	  assembly	  
based	  on	  an	  extended	  de	  Bruijn	  graph)	  for	  indels.	  
	  
4)  GNUMAP-­‐SNP	  (probabilis@c	  Pair-­‐Hidden	  Markov	  which	  effec@vely	  accounts	  for	  
uncertainty	  in	  the	  read	  calls	  as	  well	  as	  read	  mapping	  in	  an	  unbiased	  fashion),	  for	  
SNVs	  only.	  
	  
5)  BWA	  -­‐	  Sam	  format	  to	  Bam	  format	  -­‐	  Picard	  to	  remove	  duplicates	  –	  SNVer	  ,	  for	  SNVs	  
only	  
Known	   Novel	  
All	  
Total	  mean	  overlap,	  plus	  or	  minus	  one	  standard	  devia2on,	  observed	  between	  three	  
indel	  calling	  pipelines:	  GATK,	  SOAP-­‐indel,	  and	  SAMTools.	  	  a)	  Mean	  overlap	  when	  indel	  
posi@on	  was	  the	  only	  necessary	  agreement	  criterion.	  b)	  Mean	  overlap	  when	  indel	  
posi@on,	  base	  length	  and	  base	  composi@on	  were	  the	  necessary	  agreement	  criteria.	  	  	  
Indels-­‐	  Overlap	  by	  Base	  	  
Posi@on	  only	  
Indels-­‐	  Overlap	  by	  Base	  	  
Posi@on,	  Length	  and	  Composi@on	  
INDELS	  
•  How	  reliable	  are	  variants	  that	  are	  uniquely	  
called	  by	  individual	  pipelines?	  
•  Are	  some	  pipelines	  beBer	  at	  detec@ng	  rare,	  or	  
novel	  variants	  than	  others?	  
Cross	  valida@on	  using	  orthogonal	  
sequencing	  technology	  







What	  is	  the	  “True”	  Personal	  Genome?	  
35653	   19407	  17322	  
2666	  
18331	   2085	  
915	  
50.5%	   32.2%	   17.3%	  
48.6%	   45.9%	   5.5%	  
Known	   Novel	  
All	  












































Personal	  genome	  “K8101”	  
All	  
Higher	  Valida@on	  of	  SNVs	  with	  the	  
BWA-­‐GATK	  pipeline	  
•  Reveals	  higher	  valida@on	  rate	  of	  unique-­‐to-­‐
pipeline	  variants,	  as	  well	  as	  uniquely	  
discovered	  novel	  variants,	  for	  the	  variants	  
called	  by	  BWA-­‐GATK,	  in	  comparison	  to	  the	  
other	  4	  pipelines	  (including	  SOAP).	  
Much	  Higher	  Valida@on	  of	  the	  Concordantly	  
Called	  Variants	  (by	  the	  CG	  data)	  
Valida@ng	  Indels	  with	  Complete	  
Genomics	  Data	  for	  the	  3	  pipelines	  

































































Simulated	  Data	  vs.	  3	  pipelines	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Op@mizing	  pipeline	  based	  on	  literature	  value	  of	  ~1	  
true	  de	  novo	  protein-­‐altering	  muta@on	  per	  exome	  
The	  result	  is	  that	  using	  all	  of	  the	  detected	  SNVs	  for	  both	  parents	  and	  children	  should	  
minimize	  the	  false	  nega@ve	  rate	  but	  similarly	  show	  a	  rela@vely	  high	  false	  posi@ve	  rate.	  	  
Using	  all	  of	  the	  SNVs	  detected	  for	  parents	  but	  only	  the	  SNVs	  concordant	  among	  the	  five	  
pipelines	  shows	  muta@on	  rates	  similar	  to	  those	  reported	  by	  the	  literature	  and	  is	  expected	  
to	  have	  moderate	  false	  posi@ve	  rates	  and	  moderate	  false	  nega@ve	  rates.	  	  Using	  only	  the	  
SNVs	  concordant	  among	  the	  5	  different	  pipelines	  for	  both	  parents	  and	  children	  should	  
minimize	  the	  false	  posi@ve	  rate	  but	  similarly	  show	  a	  rela@vely	  high	  false	  nega@ve	  rate.	  	  	  
	  
Family 1 
Number of putative "de-novo" coding 
nonsynonymous or nonsense SNVs 
detected without using grandparent as a 
filter 
Number of putative "de-novo" coding 
nonsynonymous or nonsense SNVs detected when 
also using one grandparent as a filter 
Child A 241 1 
Child B 211 0 
Child C 102 6 
Child D 242 3 
Family 2     
Child A 49 N/A- No Grandparent available 
Child B 41 N/A - No Grandparent available 
Clinical	  Validity?	  
	  
This	  is	  SO	  complex	  that	  the	  only	  solid	  
way	  forward	  is	  with	  a	  “networking	  of	  
science”	  model,	  i.e.	  online	  database	  
with	  genotype	  and	  phenotype	  
longitudinally	  tracked.	  





•  Ancestry,	  i.e.	  gene@c	  background,	  maBers!	  
•  We	  need	  to	  sequence	  whole	  genomes	  of	  large	  
pedigrees,	  and	  then	  construct	  super-­‐family	  
structures,	  star@ng	  in	  Utah.	  
•  Collec@vely,	  we	  need	  to	  improve	  the	  accuracy	  
of	  “whole”	  genomes,	  and	  also	  enable	  the	  
sharing	  of	  genotype	  and	  phenotype	  data	  
broadly,	  among	  researchers,	  the	  research	  





Figure 4. NAT activity of recombinant hNaa10p WT or p.Ser37Pro 
towards synthetic N-terminal peptides. A) and B) Purified MBP-hNaa10p 
WT or p.Ser37Pro were mixed with the indicated oligopeptide substrates (200 
µM for SESSS and 250 µM for DDDIA) and saturated levels of acetyl-CoA 
(400 µM). Aliquots were collected at indicated time points and the acetylation 
reactions were quantified using reverse phase HPLC peptide separation. 
Error bars indicate the standard deviation based on three independent 
experiments. The five first amino acids in the peptides are indicated, for 
further details see materials and methods. Time dependent acetylation 
reactions were performed to determine initial velocity conditions when 
comparing the WT and Ser37Pro NAT-activities towards different 
oligopeptides. C) Purified MBP-hNaa10p WT or p.Ser37Pro were mixed with 
the indicated oligopeptide substrates (200 µM for SESSS and AVFAD, and 
250 µM for DDDIA and EEEIA) and saturated levels of acetyl-CoA (400 µM) 
and incubated for 15 minutes (DDDIA and EEEIA) or 20 minutes (SESSS and 
AVFAD), at 37°C in acetylation buffer. The acetylation activity was determined 
as above. Error bars indicate the standard deviation based on three 
independent experiments. Black bars indicate the acetylation capacity of the 
MBP-hNaa10p wild type (WT), while white bars indicate the acetylation 
capacity of the MBP-hNaa10p mutant p.Ser37Pro. The five first amino acids 
in the peptides are indicated. 
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